Form 4: Arcutis Biotherapeutics Director Increases Stake with Recent Share Purchases

Patrick J. Heron, a Director at Arcutis Biotherapeutics, Inc., has increased his beneficial ownership in the company by acquiring 5,040 shares of common stock through recent transactions.

Summary

• Patrick J. Heron, a Director of Arcutis Biotherapeutics, Inc. (ARQT), acquired a total of 5,040 shares of common stock over two consecutive days.
• On May 21, 2025, 2,520 shares were acquired at a price of $13.66 per share.
• On May 22, 2025, an additional 2,520 shares were acquired at a price of $13.65 per share.
• These shares were acquired indirectly through Frazier Life Sciences X, L.P., where Mr. Heron holds a managing member role in the general partner's general partner.
• Following these transactions, Mr. Heron's indirect beneficial ownership through Frazier Life Sciences X, L.P. increased to 22,534 shares.
• Mr. Heron also indirectly beneficially owns 8,785,284 shares through Frazier Life Sciences VIII, L.P., 7 shares through FHM Life Sciences VIII, L.L.C., and 23,688 shares through The Heron Living Trust 11/30/2004.
• Additionally, Mr. Heron directly owns 18,826 shares of Arcutis Biotherapeutics common stock.
• The reporting person disclaims beneficial ownership of shares held by Frazier entities except to the extent of his pecuniary interest therein.

Sentiment

Score: 7

Explanation: The sentiment is positive due to insider buying by a director, which typically signals confidence in the company's future performance and valuation. However, it's a single transaction and not a comprehensive financial report.

Positives

• A Director, Patrick J. Heron, increased his beneficial ownership in Arcutis Biotherapeutics by acquiring 5,040 shares of common stock.
• Insider buying, especially by a director, can signal confidence in the company's future prospects and valuation at the current price levels.

Negatives

• No specific negative points are indicated in this Form 4 filing, which primarily reports insider transactions.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

This Form 4 filing is a disclosure of insider trading activity and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider buying activity by a director of Arcutis Biotherapeutics, a company in the biotechnology and pharmaceutical sector, may be viewed by investors as a positive signal, potentially indicating management's belief in the company's pipeline or market position within the competitive biopharma landscape.

Related Party Transactions

• Patrick J. Heron, a Director, indirectly acquired shares through Frazier Life Sciences X, L.P., where he is one of two managing members of the general partner's general partner (FHMLS X, L.L.C.).
• He also has indirect beneficial ownership through Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C., where he holds similar managing member roles.
• Shares are also held indirectly by The Heron Living Trust 11/30/2004, where the Reporting Person is a co-trustee with voting and investment power.

Stakeholder Impact

• Shareholders may view the director's share purchases as a sign of confidence from within the company, potentially leading to increased investor interest and positive sentiment.
• Employees might interpret the insider buying as a positive indicator of the company's stability and future growth, potentially boosting morale.

Key Dates

Recommendation

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Trading, Share Purchase, Director, Beneficial Ownership, Equity Acquisition, Biotechnology, Pharmaceuticals